<p>Rigel Pharmaceuticals（納斯達克代碼：RIGL - 獲取免費報告）在週三發佈的研究報告中被 Jefferies Financial Group 的股票分析師從 “持有” 評級上調至 “買入” 評級。該券商目前對這家生物技術公司的股票設定了 42.00 美元的目標價。Jefferies Financial Group 的目標價暗示該公司股價有 10.96% 的潛在上漲空間。</p>
<p>其他研究分析師也對該公司發佈了報告。HC Wainwright 在 10 月 8 日的研究報告中重申了 “買入” 評級，並對 Rigel Pharmaceuticals 的股票設定了 57.00 美元的目標價。Weiss Ratings 在 10 月 8 日的研究報告中重申了 Rigel Pharmaceuticals 的 “持有（c+）” 評級。Cantor Fitzgerald 在週三的研究報告中將 Rigel Pharmaceuticals 的目標價從 32.00 美元上調至 38.00 美元，並給予該公司 “中性” 評級。最後，Zacks Research 在 10 月 6 日的研究報告中將 Rigel Pharmaceuticals 的評級從 “強力買入” 下調至 “持有”。三位分析師給予該股票 “買入” 評級，五位分析師給予該公司股票 “持有” 評級。根據 MarketBeat.com 的數據，Rigel Pharmaceuticals 目前的平均評級為 “持有”，共識目標價為 39.83 美元。</p>
<p>獲取 <strong>Rigel Pharmaceuticals</strong> 警報：</p>
<p><strong>獲取我們最新的 RIGL 研究報告</strong></p>
<h2>Rigel Pharmaceuticals 價格表現</h2>
<p>週三午盤交易中，RIGL 股票上漲了 9.47 美元，達到 37.85 美元。該公司股票交易量為 2,317,886 股，而其平均交易量為 383,351 股。該公司的 50 日簡單移動平均為 32.45 美元，200 日簡單移動平均為 26.00 美元。Rigel Pharmaceuticals 的 1 年最低價為 14.47 美元，1 年最高價為 43.72 美元。該公司的市值為 6.7892 億美元，市盈率為 7.00，貝塔值為 1.20。該公司的速動比率為 1.90，流動比率為 2.02，債務股本比率為 0.46。</p>
<p>Rigel Pharmaceuticals（納斯達克代碼：RIGL - 獲取免費報告）最後一次發佈季度財報是在 11 月 4 日，生物技術公司報告該季度每股收益為 1.46 美元，超出分析師共識預期的 0.93 美元，超出幅度為 0.53 美元。Rigel Pharmaceuticals 的股本回報率為 438.89%，淨利潤率為 36.51%。該公司在該季度的收入為 6946 萬美元，而分析師預期為 6188 萬美元。Rigel Pharmaceuticals 已設定 2025 財年的每股收益指導。分析師預計 Rigel Pharmaceuticals 在當前年度的每股收益為 0.22 美元。</p>
<h2>機構資金流入和流出</h2>
<p>對沖基金和其他機構投資者最近對該股票的持倉進行了調整。Armistice Capital LLC 在第一季度將其在 Rigel Pharmaceuticals 的持倉增加了 31.6%。Armistice Capital LLC 目前擁有 151.6 萬股該生物技術公司的股票，價值 27273000 美元，此前在上個季度增持了 364000 股。Acadian Asset Management LLC 在第一季度將其在 Rigel Pharmaceuticals 的持倉增加了 50.1%。Acadian Asset Management LLC 目前擁有 565045 股該生物技術公司的股票，價值 10161000 美元，此前在上個季度增持了 188679 股。Marshall Wace LLP 在第二季度將其在 Rigel Pharmaceuticals 的持倉增加了 74.2%。Marshall Wace LLP 目前擁有 368950 股該生物技術公司的股票，價值 6910000 美元，此前在上個季度增持了 157202 股。Beacon Harbor Wealth Advisors Inc.在第三季度購買了 Rigel Pharmaceuticals 的新頭寸，價值約 4310000 美元。最後，Invesco Ltd.在第一季度購買了 Rigel Pharmaceuticals 的新頭寸，價值約 2412000 美元。目前 66.23% 的股票由機構投資者持有。</p>
<h2>Rigel Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Rigel Pharmaceuticals, Inc 是一家生物技術公司，專注於發現、開發和提供增強血液疾病和癌症患者生活的療法。該公司的商業化產品包括 Tavalisse，一種用於治療慢性免疫性血小板減少症成年患者的口服脾酪氨酸激酶抑制劑；Rezlidhia，一種用於治療復發或難治性（R/R）急性髓性白血病（AML）成年患者的非強度單藥治療，適用於通過 FDA 批准的檢測發現的易感異檸檬酸脱氫酶-1（IDH1）突變；以及 GAVRETO，一種每日一次的小分子口服激酶抑制劑，用於治療轉移性重排轉錄因子（RET）融合陽性非小細胞肺癌的成年患者，以及用於治療 12 歲及以上的晚期或轉移性 RET 融合陽性甲狀腺癌的成年和兒童患者。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票比 Rigel Pharmaceuticals 更好</li>
<li>什麼是股息之王？</li>
<li>亞馬遜：突破確認——接下來可能會去哪裏</li>
<li>揭示 VWAP 的力量：交易者的關鍵指標</li>
<li>人工智能股票正在飆升——但波動性可能是下一個大考驗</li>
<li>股票股息削減發生了，你準備好了嗎？</li>
<li>西部數據的創紀錄收益證明其作為核心人工智能參與者的角色</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UklHTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UklHTA"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Rigel Pharmaceuticals 嗎？</h2>
<p>在考慮 Rigel Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Rigel Pharmaceuticals 並不在名單上。</p>
<p>雖然 Rigel Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Rigel制藥

<p>Jefferies Financial Group 將 Rigel Pharmaceuticals (NASDAQ:RIGL) 的評級從 “持有” 上調至 “買入”，設定目標價為 42.00 美元，表示潛在上漲幅度為 10.96%。其他分析師的評級則各有不同，其中三位給予 “買入” 評級，五位給予 “持有” 評級。Rigel 的股價上漲至 37.85 美元，市值為 6.7892 億美元，市盈率為 7.00。該公司報告每股收益為 1.46 美元，超出預期，季度收入為 6946 萬美元。機構投資者持有 66.23% 的股份</p>

<p>Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) was upgraded by stock analysts at Jefferies Financial Group from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note issued on Wednesday. The brokerage presently has a $42.00 price objective on the biotechnology company's stock. Jefferies Financial Group's price target suggests a potential upside of 10.96% from the company's previous close.</p>
<div class="lb-trans"><p>Rigel Pharmaceuticals（納斯達克代碼：RIGL - 獲取免費報告）在週三發佈的研究報告中被 Jefferies Financial Group 的股票分析師從 “持有” 評級上調至 “買入” 評級。該券商目前對這家生物技術公司的股票設定了 42.00 美元的目標價。Jefferies Financial Group 的目標價暗示該公司股價有 10.96% 的潛在上漲空間。</p>
</div><p>Other research analysts have also issued reports about the company. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $57.00 price objective on shares of Rigel Pharmaceuticals in a research report on Wednesday, October 8th. Weiss Ratings reiterated a &#34;hold (c+)&#34; rating on shares of Rigel Pharmaceuticals in a research report on Wednesday, October 8th. Cantor Fitzgerald increased their price objective on Rigel Pharmaceuticals from $32.00 to $38.00 and gave the company a &#34;neutral&#34; rating in a research report on Wednesday. Finally, Zacks Research lowered Rigel Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Monday, October 6th. Three analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Rigel Pharmaceuticals presently has an average rating of &#34;Hold&#34; and a consensus target price of $39.83.</p>
<div class="lb-trans"><p>其他研究分析師也對該公司發佈了報告。HC Wainwright 在 10 月 8 日的研究報告中重申了 “買入” 評級，並對 Rigel Pharmaceuticals 的股票設定了 57.00 美元的目標價。Weiss Ratings 在 10 月 8 日的研究報告中重申了 Rigel Pharmaceuticals 的 “持有（c+）” 評級。Cantor Fitzgerald 在週三的研究報告中將 Rigel Pharmaceuticals 的目標價從 32.00 美元上調至 38.00 美元，並給予該公司 “中性” 評級。最後，Zacks Research 在 10 月 6 日的研究報告中將 Rigel Pharmaceuticals 的評級從 “強力買入” 下調至 “持有”。三位分析師給予該股票 “買入” 評級，五位分析師給予該公司股票 “持有” 評級。根據 MarketBeat.com 的數據，Rigel Pharmaceuticals 目前的平均評級為 “持有”，共識目標價為 39.83 美元。</p>
</div><p>Get <strong>Rigel Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Rigel Pharmaceuticals</strong> 警報：</p>
</div><p><strong>Get Our Latest Research Report on RIGL</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 RIGL 研究報告</strong></p>
</div><h2>Rigel Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Rigel Pharmaceuticals 價格表現</h2>
</div><p>RIGL stock traded up $9.47 during midday trading on Wednesday, reaching $37.85. 2,317,886 shares of the company's stock traded hands, compared to its average volume of 383,351. The company has a 50-day simple moving average of $32.45 and a two-hundred day simple moving average of $26.00. Rigel Pharmaceuticals has a 1-year low of $14.47 and a 1-year high of $43.72. The company has a market cap of $678.92 million, a price-to-earnings ratio of 7.00 and a beta of 1.20. The company has a quick ratio of 1.90, a current ratio of 2.02 and a debt-to-equity ratio of 0.46.</p>
<div class="lb-trans"><p>週三午盤交易中，RIGL 股票上漲了 9.47 美元，達到 37.85 美元。該公司股票交易量為 2,317,886 股，而其平均交易量為 383,351 股。該公司的 50 日簡單移動平均為 32.45 美元，200 日簡單移動平均為 26.00 美元。Rigel Pharmaceuticals 的 1 年最低價為 14.47 美元，1 年最高價為 43.72 美元。該公司的市值為 6.7892 億美元，市盈率為 7.00，貝塔值為 1.20。該公司的速動比率為 1.90，流動比率為 2.02，債務股本比率為 0.46。</p>
</div><p>Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $1.46 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.53. Rigel Pharmaceuticals had a return on equity of 438.89% and a net margin of 36.51%.The firm had revenue of $69.46 million during the quarter, compared to analysts' expectations of $61.88 million. Rigel Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts anticipate that Rigel Pharmaceuticals will post 0.22 earnings per share for the current year.</p>
<div class="lb-trans"><p>Rigel Pharmaceuticals（納斯達克代碼：RIGL - 獲取免費報告）最後一次發佈季度財報是在 11 月 4 日，生物技術公司報告該季度每股收益為 1.46 美元，超出分析師共識預期的 0.93 美元，超出幅度為 0.53 美元。Rigel Pharmaceuticals 的股本回報率為 438.89%，淨利潤率為 36.51%。該公司在該季度的收入為 6946 萬美元，而分析師預期為 6188 萬美元。Rigel Pharmaceuticals 已設定 2025 財年的每股收益指導。分析師預計 Rigel Pharmaceuticals 在當前年度的每股收益為 0.22 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC lifted its holdings in Rigel Pharmaceuticals by 31.6% during the first quarter. Armistice Capital LLC now owns 1,516,000 shares of the biotechnology company's stock worth $27,273,000 after acquiring an additional 364,000 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Rigel Pharmaceuticals by 50.1% during the first quarter. Acadian Asset Management LLC now owns 565,045 shares of the biotechnology company's stock worth $10,161,000 after acquiring an additional 188,679 shares in the last quarter. Marshall Wace LLP lifted its holdings in Rigel Pharmaceuticals by 74.2% during the second quarter. Marshall Wace LLP now owns 368,950 shares of the biotechnology company's stock worth $6,910,000 after acquiring an additional 157,202 shares in the last quarter. Beacon Harbor Wealth Advisors Inc. bought a new position in Rigel Pharmaceuticals during the third quarter worth about $4,310,000. Finally, Invesco Ltd. bought a new position in Rigel Pharmaceuticals during the first quarter worth about $2,412,000. 66.23% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近對該股票的持倉進行了調整。Armistice Capital LLC 在第一季度將其在 Rigel Pharmaceuticals 的持倉增加了 31.6%。Armistice Capital LLC 目前擁有 151.6 萬股該生物技術公司的股票，價值 27273000 美元，此前在上個季度增持了 364000 股。Acadian Asset Management LLC 在第一季度將其在 Rigel Pharmaceuticals 的持倉增加了 50.1%。Acadian Asset Management LLC 目前擁有 565045 股該生物技術公司的股票，價值 10161000 美元，此前在上個季度增持了 188679 股。Marshall Wace LLP 在第二季度將其在 Rigel Pharmaceuticals 的持倉增加了 74.2%。Marshall Wace LLP 目前擁有 368950 股該生物技術公司的股票，價值 6910000 美元，此前在上個季度增持了 157202 股。Beacon Harbor Wealth Advisors Inc.在第三季度購買了 Rigel Pharmaceuticals 的新頭寸，價值約 4310000 美元。最後，Invesco Ltd.在第一季度購買了 Rigel Pharmaceuticals 的新頭寸，價值約 2412000 美元。目前 66.23% 的股票由機構投資者持有。</p>
</div><h2>Rigel Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Rigel Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.</p>
<div class="lb-trans"><p>Rigel Pharmaceuticals, Inc 是一家生物技術公司，專注於發現、開發和提供增強血液疾病和癌症患者生活的療法。該公司的商業化產品包括 Tavalisse，一種用於治療慢性免疫性血小板減少症成年患者的口服脾酪氨酸激酶抑制劑；Rezlidhia，一種用於治療復發或難治性（R/R）急性髓性白血病（AML）成年患者的非強度單藥治療，適用於通過 FDA 批准的檢測發現的易感異檸檬酸脱氫酶-1（IDH1）突變；以及 GAVRETO，一種每日一次的小分子口服激酶抑制劑，用於治療轉移性重排轉錄因子（RET）融合陽性非小細胞肺癌的成年患者，以及用於治療 12 歲及以上的晚期或轉移性 RET 融合陽性甲狀腺癌的成年和兒童患者。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Rigel Pharmaceuticals</li>
<li>What is a Dividend King?</li>
<li>Amazon: Breakout Confirmed—Here’s Where It Could Go Next</li>
<li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li>
<li>AI Stocks Are Surging—But Volatility Could Be the Next Big Test</li>
<li>Stock Dividend Cuts Happen Are You Ready?</li>
<li>Seagate's Record Earnings Prove Its Role as a Core AI Player</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比 Rigel Pharmaceuticals 更好</li>
<li>什麼是股息之王？</li>
<li>亞馬遜：突破確認——接下來可能會去哪裏</li>
<li>揭示 VWAP 的力量：交易者的關鍵指標</li>
<li>人工智能股票正在飆升——但波動性可能是下一個大考驗</li>
<li>股票股息削減發生了，你準備好了嗎？</li>
<li>西部數據的創紀錄收益證明其作為核心人工智能參與者的角色</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UklHTA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=RIGL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rigel Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Rigel Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Rigel Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Rigel Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rigel Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Rigel Pharmaceuticals 並不在名單上。</p>
</div><p>While Rigel Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Rigel Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Rigel 製藥（NASDAQ:RIGL）在 Jefferies 金融集團被上調至 “買入” 評級